The recent landscape of RSV vaccine research by Karen Kelleher, Nadisha Subramaniam, Simon B. Drysdale

Get full text

Characteristics of the First Italian Older Adults Vaccinated with an Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine by Alexander Domnich, Andrea Orsi, Piero Luigi Lai, Elvira Massaro, Carlo-Simone Trombetta, Julieta Pastorino, Charlott Roihl, Marianna Pianta, Giancarlo Icardi, Donatella Panatto

Subjects: Get full text

Attitude to RSV Vaccination Among a Cohort of Pregnant Women in Jordan: A Cross‐Sectional Survey Study by Malik Sallam, Tleen Kherfan, Amwaj Al‐Farajat, Leen Nemrawi, Nada Atawneh, Rand Fram, Ala'a B. Al‐Tammemi, Muna Barakat, Kamil Fram

“…However, vaccine hesitancy/resistance can undermine the beneficial impact of RSV vaccination. The aim of this study was to assess the willingness of pregnant women in Jordan to receive RSV vaccination and its associated determinants. …”
Get full text

The dawn of preventing respiratory syncytial virus lower respiratory tract infections in children by Z Dangor, S A Madhi, H Zar, D Demopoulos

“…Recently, two new RSV prevention strategies have emerged: nirsevimab, a long-acting monoclonal antibody, and a maternal RSV vaccine. Both strategies have shown high efficacy in reducing RSV-LRTI hospitalisation in infants and are being considered for licensure in SA. …”
Get full text

An mRNA-Based Respiratory Syncytial Virus Vaccine Elicits Strong Neutralizing Antibody Responses and Protects Rodents Without Vaccine-Associated Enhanced Respiratory Disease by Jianglong Li, Haiyan Long, Shaoyi Chen, Zhendong Zhang, Shuang Li, Qi Liu, Jun Liu, Jiaru Cai, Liping Luo, Yucai Peng

“…This study aimed to investigate the immunogenicity and efficacy of an mRNA-based RSV vaccine with an F protein sequence. Methods: We designed an mRNA construct encoding a modified RSV F protein, which was further developed into an LNP-encapsulated mRNA vaccine (LVRNA007). …”
Get full text

Respiratory syncytial virus vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Association... by Tiago Alfaro, Filipe Froes, Cláudia Vicente, Rui Costa, Cristina Gavina, Rui Baptista, António Maio, Saraiva da Cunha, João Sérgio Neves, Pedro Leuschner, Sofia Duque, Paula Pinto

“…Ongoing studies on RSV vaccines may justify extending these recommendations in the future.…”
Get full text

Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits by Jun Zhou, Christopher J. Bowman, Vicki R. Markiewicz, Balasubramanian Manickam, Emily Gomme, Rani S. Sellers, Cynthia M. Rohde

“…Pfizer has developed Abrysvo^®, an unadjuvanted bivalent recombinant protein subunit vaccine containing prefusion-stabilized fusion (F) proteins representing RSV A and RSV B subgroups (RSVpreF). It is the only RSV vaccine approved for both maternal immunization to protect infants and active immunization of older adults (≥60 years) and 18–59-year-old individuals with high-risk conditions for prevention of RSV disease. …”
Get full text

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus by Min Lin, Yifan Yin, Xiaomeng Zhao, Chen Wang, Xueqing Zhu, Letao Zhan, Li Chen, Siling Wang, Xue Lin, Jun Zhang, Ningshao Xia, Zizheng Zheng

“…Our findings suggest that LC2DM-LNP could serve as an alternative RSV vaccine candidate for high-risk groups.…”
Get full text

Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus by Xuchang Shan, Ruiwen Han, Xueting Cheng, Jialuo Bing, Zhenyong Qi, Shucai Sun, Tangqi Wang, Qiaohong Chu, Yao Deng, Desheng Zhai, Wenjie Tan

“…Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in infants and children. mRNA vaccines based on the lipopolyplex (LPP) platform have been previously reported, but they remain unapplied in RSV vaccine development. In this study, we developed a novel LPP-delivered mRNA vaccine that expresses the respiratory syncytial virus prefusion protein (RSV pre-F) to evaluate its immunogenicity and protective effect in a mouse model. …”
Get full text

Recommendation for the use of respiratory syncytial virus vaccines by Ping-Ing Lee, Yhu-Chering Huang, Ching-Chuan Liu, Shee-Uan Chen, Po-Ren Hsueh, Shih-Chi Ku, Po-Yen Chen, Chih-Jung Chen, Yi-Tsung Lin, Chun-Yi Lu, Nan-Chang Chiu, Hsin Chi, Yee-Chun Chen, Feng-Yee Chang, Muh-Yong Yen, Chin-Te Lu, Kuang-Yao Yang, Cheng-Hsun Chiu, Kao-Pin Hwang, Wen-Sen Lee, Ting-Yu Yen, Jen-Fu Hsu, Ying-Chin Lin, Ya-Li Hu, Tzou-Yien Lin

“…A committee of experts from related fields was convened by the Taiwan Immunization Vision and Strategy to develop recommendations for RSV vaccination in the elderly and pregnant women.The recommendation is not intended as a sole source of guidance in the prevention of RSV infection in children. …”
Get full text

Landscape of respiratory syncytial virus by Yuping Duan, Zimeng Liu, Na Zang, Bingbing Cong, Yuqing Shi, Lili Xu, Mingyue Jiang, Peixin Wang, Jing Zou, Han Zhang, Ziheng Feng, Luzhao Feng, Lili Ren, Enmei Liu, You Li, Yan Zhang, Zhengde Xie, Jing Ni

“…Prevention strategies remain a critical focus, with efforts centered on vaccine development and the use of prophylactic monoclonal antibodies. To date, three RSV vaccines have been approved for active immunization among individuals aged 60 years and above. …”
Get full text

DS2 designer pre-fusion F vaccine induces strong and protective antibody response against RSV infection by Yiling Yang, Ruoke Wang, Fenglin Guo, Tian Zhao, Yuqing Lei, Qianqian Yang, Yige Zeng, Ziqing Yang, Tatchapon Ajavavarakula, Ruijie Tan, Mingxi Li, Haodi Dong, Mengyue Niu, Keyan Bao, Hao Geng, Qining Lv, Qi Zhang, Xuanling Shi, Peng Liu, Jiwan Ge, Xinquan Wang, Linqi Zhang

“…These findings highlight the strong ability of the DS2 design in eliciting long-lived antibody responses and guide the development of next-generation RSV vaccines.…”
Get full text

The Impact of Vaccination on COVID-19, Influenza, and Respiratory Syncytial Virus-Related Outcomes: A Narrative Review by Roberto Debbag, Deborah Rudin, Francesca Ceddia, John Watkins

“…Based on promising results of efficacy for the prevention of RSV-associated lower respiratory tract disease, the first RSV vaccines were approved in 2023. Immunization strategies should account for various factors leading to poor uptake, including vaccine hesitancy, socioeconomic barriers to access, cultural beliefs, and lack of knowledge of vaccines and disease states. …”
Get full text

Clinical Characteristics of Virologically Confirmed Respiratory Syncytial Virus in English Primary Care: Protocol for an Observational Study of Acute Respiratory Infection by Uy Hoang, Utkarsh Agrawal, José Manuel Ordóñez-Mena, Zachary Marcum, Jennifer Radin, Andre Araujo, Catherine A Panozzo, Orsolya Balogh, Mihir Desai, Ahreej Eltayeb, Tianyi Lu, Catia Nicodemo, Xinchun Gu, Rosalind Goudie, Xuejuan Fan, Elizabeth Button, Jessica Smylie, Mark Joy, Gavin Jamie, William Elson, Rachel Byford, Joan Madia, Sneha Anand, Filipa Ferreira, Stavros Petrou, David Martin, Simon de Lusignan

“…More data would enhance our assessment of the need for an RSV vaccination program for adults in the United Kingdom. …”
Get full text